BASF SE

With his extensive background in material science, biotechnology and production environments, Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in sustainable materials, has announced that David Williamson, PhD, will transition from president and chief operating officer (COO) to chief executive officer (CEO), effective October 14, 2024. Dr. Williamson has served in multiple roles within the company since 2015 and will now spearhead its next phase of growth. As CEO, Dr. Williamson will continue executing on the company's strategic growth plan to create sustainable biofabricated materials that offer new levels of performance, sustainability and design possibilities. Continue Reading Dr. Williamson has served in multiple roles within Modern Meadow since 2015 and will now spearhead its next phase of growth as CEO. Post this With his extensive background in material science, biotechnology and production environments, Dr. Williamson will continue executing on Modern Meadow's strategic growth plan to create sustainable biofabricated materials that offer new levels of performance, sustainability and design possibilities, like BIO-VERA. "All of us at Modern Meadow have a passion for technology and innovation, and I am proud to lead us into our next chapter as we continue to advance our mission of commercializing transformative sustainable alternative materials, such as BIO-VERA," Dr. Williamson said. "Modern Meadow is at a pivotal stage – one in which we are building on our major production milestone to produce 500,000 square meters per year of our BIO-VERA. This milestone highlights the market readiness and cost-efficiency of BIO-VERA, positioning Modern Meadow to meet increasing demand from original equipment manufacturers (OEMs), brands and premium tanneries that are actively adopting the material." Modern Meadow's strategy includes: Streamlining operations for increased efficiency Expanding its European market presence Supporting commercialization and brand adoption efforts by extending its operational runway. The company will also continue to strengthen and expand the BIO-VERA brand by developing refreshed brand messaging, in close collaboration with its commercial partners, to bring the brand to life for consumers and industry alike. About Modern Meadow Modern Meadow is focused on creating innovative biomaterials that make a positive impact on the world. Its main product, BIO-VERA®, is a transformative new sustainable material that is not only beautiful, but stronger and lighter than traditional materials. Made with over 90% renewable carbon content, BIO-VERA is crafted using Bio-Alloy™, a flexible mix of proteins and polymers. This approach allows Modern Meadow to reduce reliance on oil-based and animal products without sacrificing quality. BIO-VERA is designed to easily integrate into existing production processes used by industries such as automotive, footwear, furniture and fashion accessories, making it a practical option for immediate use. Modern Meadow works closely with top brands like Tory Burch and industry leaders like BASF, Bader and ISA TanTec to ensure its products are of the highest quality and fully traceable from its lab to the brands people love. For more information, visit modernmeadow.com or follow the company on LinkedIn and Instagram. Media Contact Jordan Vines +1 (540) 629-3137 [email protected] BIO-VERA is a registered trademark of Modern Meadow, Inc. SOURCE Modern Meadow WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN--( BUSINESS WIRE )--The "Biopharmaceutical Excipients Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical Excipients Market was valued at USD 2.43 billion in 2023, and is expected to reach USD 3.79 billion by 2029, rising at a CAGR of 7.69% The global biopharmaceutical excipients market report contains exclusive data on 36 vendors. The market is characterized by diverse vendors, from emerging mid-sized companies to well-established players, contributing to its revenue. Leading companies are employing various strategies to increase their market share and presence. These include launching new products, securing approvals, engaging in marketing and promotional activities, investing heavily in R&D, and strengthening their distribution networks. Major players such as Merck KGaA, BASF SE, Avantor, Evonik Industries, Roquette Freres, Associated British Foods, and others are also focusing on strategic licensing, acquisitions, and collaboration agreements with emerging companies to quickly enter the biopharmaceutical excipients market and access commercially available products. Expanding into existing and new markets to meet the needs of a growing customer base, broadening product portfolios, and enhancing production capabilities are key strategies to attract end-users. Additionally, companies are introducing advanced and novel excipient solutions to support pharmaceutical drug development, ensuring robust distribution chains to meet market demand. APAC shows significant growth, with the fastest-growing region in the global biopharmaceutical excipients market. The APAC region is poised for significant growth, driven by several key factors. The region's expanding pharmaceutical industry, advancements in functional excipients, and the rising use of orphan drugs underscore robust growth prospects. The emergence of multifunctional excipients and the shift of pharmaceutical manufacturing to emerging markets further enhance these prospects. Additionally, the burgeoning biosimilar industry in APAC presents new opportunities for excipients used in biopharmaceutical formulations. The region is witnessing an increasing target patient population, particularly those affected by cancer, which remains the second-highest cause of death globally. MARKET TRENDS & DRIVERS Demand for Novel Excipients in Advancing Biopharmaceutical Development Developing new and improved biopharmaceutical drugs relies on novel excipients essential for advanced product formulations. Unlike conventional excipients, these novel substances have not been used in FDA-approved drug products and lack established food use. Advocates highlight their public health benefits, including enhanced drug delivery and their utility in abuse-deterrent opioid formulations. Recognition by the FDA as novel excipients would assure drug developers of their safety, reducing concerns during application review. While many approved drug excipients are listed in the FDA's Inactive Ingredient Database (IID) and have been used for decades, novel excipients are typically not included in the IID. They may be intended for new administration routes, higher dosages, or modifications like particle engineering. In a significant step towards modernizing drug formulation, the FDA has initiated a program to test the safety and suitability of novel inactive ingredients for new drugs and biologics. This initiative encourages using novel excipients in clinical trials, providing excipient suppliers with a faster route to market and promoting innovative therapies. Increasing Demand for Excipients in Vaccine and Regenerative Medicine Formulations Excipients play a critical role in stabilizing vaccines and developing regenerative medicines, ensuring safety, stability, and efficacy. Vaccines, inherently unstable and prone to degradation, require various excipients like diluents, preservatives, stabilizers, adjuvants, and buffering agents. For instance, preservatives such as formaldehyde prevent contamination, while stabilizers like sucrose and gelatin maintain potency during storage and transport. Aluminum salts are used as adjuvants, enhancing immune response, and buffering agents like sodium chloride maintain pH balance. In regenerative medicine, the demand for novel excipients is rising, driven by the growth in cell and gene therapies to treat rare diseases. These therapies utilize excipients such as buffers, salts, polymers, and proteins to stabilize formulations and ensure physiological osmolality. The investment in cell and gene therapy has surged, necessitating innovative excipients to support the development of advanced therapeutic solutions. Strategic Outsourcing in Biopharmaceutical Excipient Manufacturing Pharmaceutical companies are increasingly outsourcing the manufacturing of biopharmaceutical excipients due to several key factors. Rapid advancements in biopharmaceutical R&D have created a need for specialized excipients that enhance drug efficacy, stability, and delivery, requiring complex and costly manufacturing processes. Outsourcing allows pharmaceutical firms to focus on core activities like drug discovery, clinical trials, and regulatory affairs, leveraging the expertise of specialized manufacturers to streamline operations and accelerate market entry for new therapies. Outsourcing also provides flexibility and scalability, enabling companies to adjust capacity and maintain compliance with evolving regulatory standards, ensuring a reliable supply chain. Additionally, it offers cost-effectiveness by reducing the capital expenditures for in-house manufacturing facilities and allowing more efficient resource allocation while maintaining high-quality standards. The need for innovation, operational efficiency, regulatory compliance, and cost savings drives the trend toward outsourcing. INDUSTRY RESTRAINTS Supply Chain and Integrity Issues with Biopharmaceutical Excipients The integrity and reliability of the biopharmaceutical excipient supply chain are crucial for the quality and efficacy of biopharmaceutical products. This complex global supply chain, involving multiple suppliers and distributors, poses significant challenges. Though pharmacologically inert, excipients require strict management to prevent adulteration and ensure patient safety. The rise of novel excipients and delivery systems amplifies the need for robust quality control, certification, and supply chain management. The extended supply chains and increased importation introduce risks of counterfeit or substandard excipients, potentially causing production delays and adverse effects. Ensuring compliance with Good Manufacturing Practices (GMP) and regulatory standards is essential. Historical incidents, such as the 2012 contamination with industrial-grade gelatin, highlight the importance of strict controls. Regulatory bodies like the FDA and China's SFDA have enforced stricter regulations on high-risk excipients. To maintain market growth, pharmaceutical manufacturers must prioritize high-quality excipients, adhering to stringent regulatory requirements despite the complexities of the supply chain. KEY QUESTIONS ANSWERED: How big is the global biopharmaceutical excipients market? What is the growth rate of the global biopharmaceutical excipients market? What are the key trends in the global biopharmaceutical excipients market? Which region shows the highest growth in the global biopharmaceutical excipients market? Who are the major players in the global biopharmaceutical excipients market? Key Attributes: Report Attribute Details No. of Pages 163 Forecast Period 2023 - 2029 Estimated Market Value (USD) in 2023 $2.43 Billion Forecasted Market Value (USD) by 2029 $3.79 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Vendors Merck KGaA BASF SE Avantor Evonik Industries AG Roquette Freres Associated British Foods plc Other Prominent Vendors Actylis Advancion Apothecon Pharmaceuticals Ashland BioSpectra BOC Sciences CG Group Clariant Colorcon DFE Pharma Dow Eastman Chemical Company IMCD Innophos InVitria ABITEC CordenPharma Croda International plc JRS Pharma Kirsch Pharma MEGGLE Novo Nordisk Pfanstiehl Shin-Etsu Chemical Sigachi Industries Spectrum Chemical Stepan Company Tereos The Lubrizol Corporation WACKER CHEMI By Excipient Bulking Agents Solubilizers & Surfactants Buffering & Tonicity Agents Others By Biologics Monoclonal Antibodies Vaccines Others By Scale of Operation Commercial Research By Origin Organic Excipients Inorganic Excipients By End-User Pharma & Biotech Companies CMOs & CDMOs Academic & Research Institutes By Geography North America The U.S. Canada Europe Germany The U.K. France Italy Spain APAC Japan China India Australia South Korea Latin America Brazil Mexico Argentina Middle East & Africa Turkey South Africa Saudi Arabia For more information about this report visit https://www.researchandmarkets.com/r/7oy3j7 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Blue Shield of California is adding more resources for members to improve gut health and lose weight. Digital health platform Wellvolution by Blue Shield of California has expanded its offerings to include four new programs. The additions, which launched in mid-May, are Ciba Health, Digbi Health, Wondr Health and an expansion of the DarioHealth platform. Wellvolution announced it would include Dario in September for English and Spanish speakers to reduce and track hypertension. Launched in 2019, Wellvolution has now reached its five-year anniversary mark, serving more than 355,000 members and helping them lose more than 272,000 pounds. The platform includes programs that combine education with instruction to help people enjoy healthier lives. “We launched Wellvolution in 2019 to help our members prevent, treat and even reverse chronic diseases with lifestyle medicine at no additional cost,” said Angie Kalousek Ebrahimi, senior director of lifestyle medicine at Blue Shield of California, in a statement. “Lifestyle medicine, paired with personalized health coaching and digital tools and technologies, can transform lives.” Ciba Health is designed to focus on the root cause of disease by making small changes to diets to reverse diabetes and obesity, explained a Blue Shield of California spokesperson. DarioHealth’s diabetes management program also joined the Wellvolution lineup in May. It offers a blood sugar testing device that is plugged into a member’s phone, test strips and lancets to help members and coaches better track blood sugar management. Wondr Health analyzes behavior change to help members lose weight in the long term by improving sleep and reducing stress, among other factors. If members use Digbi Health, they can access an at-home gut microbiome test kit. Digbi Health experts create a “custom treatment plan” for food and medications, the Blue Shield of California spokesperson said. Digbi is offered for members who qualify for the diabetes prevention program that includes criteria like family history and BMI. “Over the past five years, we have worked closely with Blue Shield of California to guide members to personalized digital health solutions addressing an expanding array of chronic conditions,” said John Santelli, interim CEO at digital health benefits marketplace Solera Health, with which the insurer partnered to build Wellvolution. “We pride ourselves on curating a comprehensive, high-quality network, and look forward to continuing our work with Blue Shield to improve the lives of Californians by preventing and improving a range of health conditions.”